Using proteomics, we showed that the NF2−/− tumours divided into two distinct groups with distinct underlying mutational spectrum, NF2 clusters 1 and 2, independent of NF2 severity score, chromosome loss, CDKN2A/B and TERT mutations (Fig. 5). The gene discussed is NF2; the disease is neoplasm.